Literature DB >> 18602263

In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle.

Libero Vitiello1, Nicola Bassi, Paola Campagnolo, Eva Zaccariotto, Gianluca Occhi, Alberto Malerba, Sarah Pigozzo, Carlo Reggiani, Simonetta Ausoni, Tania Zaglia, Piergiorgio Gamba, Maurizio D Baroni, Andrea P Ditadi.   

Abstract

Antisense-mediated exon skipping holds great potential for the treatment of DMD. In mdx mice, functional recovery of skeletal muscle has been obtained upon systemic delivery of "naked" oligonucleotides or viral vectors encoding for antisense snRNAs. However, amongst the studies reported so far, which used either neonatal or young adult animals--only one achieved dystrophin restoration in cardiac muscle, using an adeno-associated vector. Here we report the in vivo delivery of morpholino oligos in aged mdx mice, both in skeletal muscle, via intra-arterial injection, and in cardiac muscle, via intra-muscular injection. Localized intra-arterial delivery yielded high levels of dystrophin restoration and just two doses of 100 microg each resulted into detectable force recovery in the EDL muscles of treated limbs. On the other hand, upon intra-cardiac injections in the left ventricle wall the skipping effect was much lower than what obtained in tibialis anterior muscles injected with comparable amounts of oligos. This latter finding suggests that even upon direct delivery antisense-mediated dystrophin restoration in cardiac muscle might suffer from limitations that do not exist in skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602263     DOI: 10.1016/j.nmd.2008.05.011

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

1.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

Authors:  Paul S Sharp; Hema Bye-a-Jee; Dominic J Wells
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

3.  Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD).

Authors:  Camilla Brolin; Takehiko Shiraishi
Journal:  Artif DNA PNA XNA       Date:  2011-01

4.  Restoration of Functional Full-Length Dystrophin After Intramuscular Transplantation of Foamy Virus-Transduced Myoblasts.

Authors:  Jinhong Meng; Nathan Paul Sweeney; Bruno Doreste; Francesco Muntoni; Myra McClure; Jennifer Morgan
Journal:  Hum Gene Ther       Date:  2020-01-10       Impact factor: 5.695

Review 5.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 6.  Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.

Authors:  Bo Bao; Rika Maruyama; Toshifumi Yokota
Journal:  Intractable Rare Dis Res       Date:  2016-08

7.  Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.

Authors:  HaiFang Yin; Corinne Betts; Amer F Saleh; Gabriela D Ivanova; Hyunil Lee; Yiqi Seow; Dalsoo Kim; Michael J Gait; Matthew J A Wood
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

Review 8.  Progress in therapeutic antisense applications for neuromuscular disorders.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

9.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10

10.  Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.

Authors:  Corinne Betts; Amer F Saleh; Andrey A Arzumanov; Suzan M Hammond; Caroline Godfrey; Thibault Coursindel; Michael J Gait; Matthew Ja Wood
Journal:  Mol Ther Nucleic Acids       Date:  2012-08-14       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.